Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Jan 8;19:111–128. doi: 10.2147/DDDT.S478692

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2025 Duan et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Neuroprotective effects of remimazolam in brain ischemia/reperfusion (I/R) injury. (A) 2,3,5-triphenyltetrazolium chloride (TTC) staining of rat brain tissue. (B) Infarct volume in rat brain sections. (C) Scoring of neurological deficits in rats. (D) Hematoxylin-eosin (HE) staining of rat brain coronal sections. n=3. (E) SY5Y cell viability in normal and hypoxia-reoxygenation states after post-treatment (0-150 μg/mL) with remimazolam. (F) SY5Y cell viability in groups post-treated (100 μg/mL) with remimazolam. n=3. *P<0.05, **P<0.01, ***P<0.001.